J. Jauch-Lembach

GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods

J. Poetzl, O. von Richter, Lena Lemke, 2019, Expert opinion on biological therapy.

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

Ines Brueckmann, P. Wiland, N. Gaylis, 2020, BioDrugs.

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

A. Blauvelt, C. Leonardi, J. Fowler, 2018, The British journal of dermatology.

FRI0087 EFFICACY, SAFETY, AND IMMUNOGENICITY RESULTS OF THE SWITCH FROM REFERENCE ADALIMUMAB (REFADL) TO SANDOZ BIOSIMILAR ADALIMUMAB (GP2017, SDZ-ADL) FROM ADMYRA PHASE 3 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS (RA)

P. Wiland, N. Gaylis, S. Jeka, 2019, Poster Presentations.

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

A. Blauvelt, C. Leonardi, Ines Brueckmann, 2021, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

A. Blauvelt, C. Leonardi, Ines Brueckmann, 2021, BioDrugs.